www.rinvoq.com
Open in
urlscan Pro
2600:9000:223e:a200:5:8ced:94c0:93a1
Public Scan
Submitted URL: http://psoriaticarthritisrinvoq.health/
Effective URL: https://www.rinvoq.com/psoriatic-arthritis
Submission: On December 16 via api from TR — Scanned from DE
Effective URL: https://www.rinvoq.com/psoriatic-arthritis
Submission: On December 16 via api from TR — Scanned from DE
Form analysis 2 forms found in the DOM
Name: abbv-send-email — POST #
<form action="#" class="abbv-send-email-form" method="post" name="abbv-send-email"
data-share-api="/content/rinvoq/en-us/psoriatic-arthritis/jcr:content/contentpar/container_989899757/containerparsys/container_copy/containerparsys/container_457343190_/containerparsys/columns/0/container_copy_679792154/containerparsys/container_copy/containerparsys/send_mail">
<a aria-hidden="true" style="display:none" id="abbv-email-share-url"></a>
<p></p>
<div class="abbv-form-wrapper abbv-to-email">
<div class="label-wrapper">
<label class="abbv-label-text" for="Text"> Enter your email address</label>
<button class="abbv-button-plain more-info abbv-icon-info i-a"></button>
</div>
<input type="text" class="abbv-toEmail" placeholder="johndoe@email.com" name="toEmail" data-required="true">
<p class="abbv-additional-info"></p>
<span class="abbv-error-msg" data-err-msg="Please enter a valid email address."></span>
</div>
<div class="abbv-mail-buttons">
<button class="abbv-button-primary abbv-cancel-email"></button>
<button class="abbv-button-primary abbv-submit-email">Send email</button>
</div>
<div class="abbv-badgeless-captcha"> This site is protected by reCAPTCHA and the Google <a href="https://policies.google.com/privacy" target="_blanK">Privacy Policy</a> and
<a href="https://policies.google.com/terms" target="_blanK">Terms of Service</a> apply. </div>
<div class="g-recaptcha js-v2" data-sitekey="6Ld-4xkiAAAAAIqU4DUDupoGer6ss43KQeOGEtk0" data-badge="inline" data-size="invisible">
<div class="grecaptcha-badge" data-style="inline" style="width: 256px; height: 60px; box-shadow: gray 0px 0px 5px;">
<div class="grecaptcha-logo"><iframe title="reCAPTCHA" width="256" height="60" role="presentation" name="a-gt7ndnmjs0wr" frameborder="0" scrolling="no"
sandbox="allow-forms allow-popups allow-same-origin allow-scripts allow-top-navigation allow-modals allow-popups-to-escape-sandbox allow-storage-access-by-user-activation"
src="https://www.google.com/recaptcha/enterprise/anchor?ar=1&k=6Ld-4xkiAAAAAIqU4DUDupoGer6ss43KQeOGEtk0&co=aHR0cHM6Ly93d3cucmludm9xLmNvbTo0NDM.&hl=de&v=u-xcq3POCWFlCr3x8_IPxgPu&size=invisible&badge=inline&cb=u8csmboo0mi9"></iframe>
</div>
<div class="grecaptcha-error"></div><textarea id="g-recaptcha-response" name="g-recaptcha-response" class="g-recaptcha-response"
style="width: 250px; height: 40px; border: 1px solid rgb(193, 193, 193); margin: 10px 25px; padding: 0px; resize: none; display: none;"></textarea>
</div>
</div>
</form>Name: abbv-send-email — POST #
<form action="#" class="abbv-send-email-form" method="post" name="abbv-send-email"
data-share-api="/content/rinvoq/en-us/psoriatic-arthritis/jcr:content/contentpar/container_989899757/containerparsys/container_copy/containerparsys/container_457343190_/containerparsys/columns/0/container_copy_679792154/containerparsys/container_copy/containerparsys/send_mail_copy">
<a aria-hidden="true" style="display:none" id="abbv-email-share-url"></a>
<p></p>
<div class="abbv-form-wrapper abbv-to-email">
<div class="label-wrapper">
<label class="abbv-label-text" for="Text"> Enter your email address</label>
<button class="abbv-button-plain more-info abbv-icon-info i-a"></button>
</div>
<input type="text" class="abbv-toEmail" placeholder="johndoe@email.com" name="toEmail" data-required="true">
<p class="abbv-additional-info"></p>
<span class="abbv-error-msg" data-err-msg="Please enter a valid email address."></span>
</div>
<div class="abbv-mail-buttons">
<button class="abbv-button-primary abbv-cancel-email"></button>
<button class="abbv-button-primary abbv-submit-email">Send email</button>
</div>
<div class="abbv-badgeless-captcha"> This site is protected by reCAPTCHA and the Google <a href="https://policies.google.com/privacy" target="_blanK">Privacy Policy</a> and
<a href="https://policies.google.com/terms" target="_blanK">Terms of Service</a> apply. </div>
<div class="g-recaptcha js-v2" data-sitekey="6Ld-4xkiAAAAAIqU4DUDupoGer6ss43KQeOGEtk0" data-badge="inline" data-size="invisible">
<div class="grecaptcha-badge" data-style="inline" style="width: 256px; height: 60px; box-shadow: gray 0px 0px 5px;">
<div class="grecaptcha-logo"><iframe title="reCAPTCHA" width="256" height="60" role="presentation" name="a-agom5nqoolyd" frameborder="0" scrolling="no"
sandbox="allow-forms allow-popups allow-same-origin allow-scripts allow-top-navigation allow-modals allow-popups-to-escape-sandbox allow-storage-access-by-user-activation"
src="https://www.google.com/recaptcha/enterprise/anchor?ar=1&k=6Ld-4xkiAAAAAIqU4DUDupoGer6ss43KQeOGEtk0&co=aHR0cHM6Ly93d3cucmludm9xLmNvbTo0NDM.&hl=de&v=u-xcq3POCWFlCr3x8_IPxgPu&size=invisible&badge=inline&cb=tbhzndxku9wg"></iframe>
</div>
<div class="grecaptcha-error"></div><textarea id="g-recaptcha-response-1" name="g-recaptcha-response" class="g-recaptcha-response"
style="width: 250px; height: 40px; border: 1px solid rgb(193, 193, 193); margin: 10px 25px; padding: 0px; resize: none; display: none;"></textarea>
</div><iframe style="display: none;"></iframe>
</div>
</form>Text Content
Learn how AbbVie could help you save on RINVOQ.
Call 1-800-2RINVOQ or click to learn more >
Skip to Main content
* Important Safety Information
* Full Prescribing Information & Patient Information
* Full Prescribing Information (English)
* Medication Guide
* Healthcare Professionals Site
* View All Conditions
* 1-800-2RINVOQ
* Cost & Savings
* Sign up for RINVOQ updates
*
* About PsA
* PsA Treatment Options
* Goals for PsA
* About RINVOQ
* What is RINVOQ?
* RINVOQ Results
* Patient Stories
* Taking RINVOQ
* Understanding Side Effects
* Getting RINVOQ
* Partner With a Rheumatologist
* Find a Rheumatologist
* Appointment Checklist
* RINVOQ Resources
* About RINVOQ Complete
* Save on RINVOQ
* Your Nurse Ambassador
* RINVOQ Complete App
* Preparing for RINVOQ
* Insurance Explained
* Building Your Routine
* 1-800-2RINVOQ
* Cost & Savings
* Sign Up for RINVOQ Updates
* View All Conditions
*
* Important Safety Information
* Full Prescribing Information & Patient Information
* Full Prescribing Information (English)
* Medication Guide
* Healthcare Professionals Site
* View All Conditions
IMPORTANT SAFETY INFORMATION & USE
Warning: Serious Infections, Increased Risk of Death, Cancer, Major
Cardiovascular Events, Blood Clots
If you’re still experiencing PsA symptoms
after a TNF blocker like HUMIRA® or ENBREL® ,
RINVOQ is
and may help
See RINVOQ Results
RINVOQ is a JAK inhibitor for adults with active psoriatic arthritis (PsA) in
whom TNF blockers did not work well.
If you’re still experiencing PsA symptoms after a TNF blocker like HUMIRA® or
ENBREL® ,
RINVOQ is
and may help
See RINVOQ Results
RINVOQ is a JAK inhibitor for adults with active psoriatic arthritis (PsA) in
whom TNF blockers did not work well.
TACKLE PSORIATIC ARTHRITIS SYMPTOMS WITH RINVOQ
Proven in clinical studies, RINVOQ can:
Significantly relieve joint pain, swelling, and stiffness for the majority of
people in 3 months—for some, PsA symptoms improved in just 2 weeks
Leave skin* clear or almost clear for people with skin plaques
*RINVOQ is not approved to treat plaque psoriasis.
Stop further irreversible joint damage
Significantly reduce PsA fatigue
See how RINVOQ works
--------------------------------------------------------------------------------
RINVOQ IS A ONCE-DAILY PILL, NOT AN INJECTION.
Not actual size.
Select Important Safety Information
RINVOQ may cause serious side effects, including:
* Serious Infections, Cancer and Immune System Problems, and Blood Clots.
* Increased risk of death in people age 50+ with at least 1 heart disease risk
factor.
* Increased risk of major cardiovascular events, such as heart attack, stroke,
or death in people age 50+ with at least 1 heart disease risk factor,
especially in current or past smokers.
* Serious allergic reactions. Do not take if allergic to RINVOQ or its
ingredients.
Learn more about these and other serious side effects >
See full Important Safety Information below.
Have you ever been prescribed a TNF blocker for psoriatic arthritis (PsA)?
Yes, I've been prescribed a TNF blocker No, I haven't I'm not sure Not yet
diagnosed
If you’re still experiencing PsA symptoms after a TNF blocker like HUMIRA® or
ENBREL®, RINVOQ, a JAK inhibitor, is different and may help. See RINVOQ Results
>
A rheumatologist is your best partner to finding a treatment plan that can help
you reach your goals. Partner With a Rheumatologist >
Play an active part in your PsA treatment plan—staying engaged can help you
manage PsA symptoms and reach your treatment goals. Partner With a
Rheumatologist >
A rheumatologist can evaluate your PsA symptoms and help create a treatment plan
that meets your unique needs. Find a Rheumatologist >
HUMIRA® and ENBREL® are examples of TNF blockers. ENBREL® (etanercept) is a
registered trademark of Immunex Corporation in the US.
>95% OF PEOPLE WITH INSURANCE ARE COVERED FOR RINVOQ
>95% of people with self- or employer-provided insurance plans or Medicare Part
D are covered for RINVOQ.†
The RINVOQ Complete Savings Card may help eligible commercially insured patients
pay as little as $5 a month‡ for RINVOQ.
See how you can save
INSPIRING STORIES, REAL RESULTS
Hear how Tim takes on PsA with RINVOQ.
Watch Tim’s story
Hear how Tim takes on PsA with RINVOQ.
Watch Tim’s story
STAY IN THE KNOW
Sign up for the latest tips, tools, and information to help you take PsA head
on.
Become a RINVOQ Insider
SHARE YOUR RINVOQ STORY
Share your experience with RINVOQ to help inform and inspire others. To
participate, please email us at info@SPEAKnetwork.net or call 877-861-6180.
Email or download the brochure to learn more about RINVOQ.
Please choose one
English
Español
Enter your email address
Send email
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of
Service apply.
Enter your email address
Send email
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of
Service apply.
Download brochure PDF
Descargar el folleto en Español
ENBREL® (etanercept) is a registered trademark of Immunex Corporation in the US.
†National Commercial and Medicare Part D formulary coverage as of June 2023.
‡Eligibility: Available to patients with commercial insurance coverage for
RINVOQ® (upadacitinib) who meet eligibility criteria. This co-pay assistance
program is not available to patients receiving prescription reimbursement under
any federal, state, or government-funded insurance programs (for example,
Medicare [including Part D], Medicare Advantage, Medigap, Medicaid, TRICARE,
Department of Defense, or Veterans Affairs programs) or where prohibited by law.
Offer subject to change or termination without notice. Restrictions, including
monthly maximums, may apply. This is not health insurance. For full Terms and
Conditions, visit RINVOQSavingsCard.com or call 1.800.2RINVOQ for additional
information. To learn about AbbVie’s privacy practices and your privacy choices,
visit https://privacy.abbvie
USE
RINVOQ is a prescription medicine used to treat adults with active psoriatic
arthritis when 1 or more medicines called tumor necrosis factor (TNF) blockers
have been used, and did not work well or could not be tolerated. It is not known
if RINVOQ is safe and effective in children with psoriatic arthritis.
IMPORTANT SAFETY INFORMATION
What is the most important information I should know about RINVOQ?
RINVOQ may cause serious side effects, including:
* Serious infections. RINVOQ can lower your ability to fight infections.
Serious infections have happened while taking RINVOQ, including tuberculosis
(TB) and infections caused by bacteria, fungi, or viruses that can spread
throughout the body. Some people have died from these infections. Your
healthcare provider (HCP) should test you for TB before starting RINVOQ and
check you closely for signs and symptoms of TB during treatment with RINVOQ.
You should not start taking RINVOQ if you have any kind of infection unless
your HCP tells you it is okay. If you get a serious infection, your HCP may
stop your treatment until your infection is controlled. You may be at higher
risk of developing shingles (herpes zoster).
* Increased risk of death in people 50 years and older who have at least 1
heart disease (cardiovascular) risk factor.
* Cancer and immune system problems. RINVOQ may increase your risk of certain
cancers. Lymphoma and other cancers, including skin cancers, can happen.
Current or past smokers are at higher risk of certain cancers, including
lymphoma and lung cancer. Follow your HCP's advice about having your skin
checked for skin cancer during treatment with RINVOQ. Limit the amount of
time you spend in sunlight. Wear protective clothing when you are in the sun
and use sunscreen.
* Increased risk of major cardiovascular (CV) events, such as heart attack,
stroke, or death, in people 50 years and older who have at least 1 heart
disease (CV) risk factor, especially if you are a current or past smoker.
* Blood clots. Blood clots in the veins of the legs or lungs and arteries can
happen with RINVOQ. This may be life-threatening and cause death. Blood clots
in the veins of the legs and lungs have happened more often in people who are
50 years and older and with at least 1 heart disease (CV) risk factor.
* Allergic reactions. Symptoms such as rash (hives), trouble breathing, feeling
faint or dizzy, or swelling of your lips, tongue, or throat, that may mean
you are having an allergic reaction have been seen in people taking RINVOQ.
Some of these reactions were serious. If any of these symptoms occur during
treatment with RINVOQ, stop taking RINVOQ and get emergency medical help
right away.
* Tears in the stomach or intestines. This happens most often in people who
take nonsteroidal anti-inflammatory drugs (NSAIDs) or corticosteroids. Get
medical help right away if you get stomach-area pain, fever, chills, nausea,
or vomiting.
* Changes in certain laboratory tests. Your HCP should do blood tests before
you start taking RINVOQ and while you take it. Your HCP may stop your RINVOQ
treatment for a period of time if needed because of changes in these blood
test results.
Do not take RINVOQ if you are allergic to upadacitinib or any of the ingredients
in RINVOQ. See the Medication Guide or Consumer Brief Summary for a complete
list of ingredients.
What should I tell my HCP BEFORE starting RINVOQ?
Tell your HCP if you:
* Are being treated for an infection, have an infection that won't go away or
keeps coming back, or have symptoms of an infection, such as:
* - Fever, sweating, or chills
* - Shortness of breath
* - Warm, red, or painful skin or sores on your body
* - Muscle aches
* - Feeling tired
* - Blood in phlegm
* - Diarrhea or stomach pain
* - Cough
* - Weight loss
* - Burning when urinating or urinating more often than normal
* Have TB or have been in close contact with someone with TB.
* Are a current or past smoker.
* Have had a heart attack, other heart problems, or stroke.
* Have or have had any type of cancer, hepatitis B or C, shingles (herpes
zoster), blood clots in the veins of your legs or lungs, diverticulitis
(inflammation in parts of the large intestine), or ulcers in your stomach or
intestines.
* Have other medical conditions, including liver problems, low blood cell
counts, diabetes, chronic lung disease, HIV, or a weak immune system.
* Live, have lived, or have traveled to parts of the country, such as the Ohio
and Mississippi River valleys and the Southwest, that increase your risk of
getting certain kinds of fungal infections. If you are unsure if you've been
to these types of areas, ask your HCP.
* Have recently received or are scheduled to receive a vaccine. People who take
RINVOQ should not receive live vaccines.
* Are pregnant or plan to become pregnant. Based on animal studies, RINVOQ may
harm your unborn baby. Your HCP will check whether or not you are pregnant
before you start RINVOQ. You should use effective birth control
(contraception) to avoid becoming pregnant during treatment with RINVOQ and
for 4 weeks after your last dose.
* There is a pregnancy surveillance program for RINVOQ. The purpose of the
program is to collect information about the health of you and your baby. If
you become pregnant while taking RINVOQ, you are encouraged to report the
pregnancy by calling 1-800-633-9110.
* Are breastfeeding or plan to breastfeed. RINVOQ may pass into your breast
milk. Do not breastfeed during treatment with RINVOQ and for 6 days after
your last dose.
Tell your HCP about all the medicines you take, including prescription and
over-the-counter medicines, vitamins, and herbal supplements. RINVOQ and other
medicines may affect each other, causing side effects.
Especially tell your HCP if you take:
* Medicines for fungal or bacterial infections
* Rifampicin or phenytoin
* Medicines that affect your immune system
If you are not sure if you are taking any of these medicines, ask your HCP or
pharmacist.
What should I avoid while taking RINVOQ?
Avoid food or drink containing grapefruit during treatment with RINVOQ as it may
increase the risk of side effects.
What should I do or tell my HCP AFTER starting RINVOQ?
* Tell your HCP right away if you have any symptoms of an infection. RINVOQ can
make you more likely to get infections or make any infections you have worse.
* Get emergency help right away if you have any symptoms of a heart attack or
stroke while taking RINVOQ, including:
* - Discomfort in the center of your chest that lasts for more than a few
minutes or that goes away and comes back
* - Severe tightness, pain, pressure, or heaviness in your chest, throat,
neck, or jaw
* - Pain or discomfort in your arms, back, neck, jaw, or stomach
* - Shortness of breath with or without chest discomfort
* - Breaking out in a cold sweat
* - Nausea or vomiting
* - Feeling lightheaded
* - Weakness in one part or on one side of your body
* - Slurred speech
* Tell your HCP right away if you have any signs or symptoms of blood clots
during treatment with RINVOQ, including:
* - Swelling
* - Pain or tenderness in one or both legs
* - Sudden unexplained chest or upper back pain
* - Shortness of breath or difficulty breathing
*
*
* Tell your HCP right away if you have a fever or stomach-area pain that does
not go away, and a change in your bowel habits.
What are other possible side effects of RINVOQ?
Common side effects include upper respiratory tract infections (common cold,
sinus infections), shingles (herpes zoster), herpes simplex virus infections
(including cold sores), bronchitis, nausea, cough, fever, acne, headache,
increased blood levels of creatine phosphokinase, allergic reactions,
inflammation of hair follicles, stomach-area (abdominal) pain, increased weight,
flu, tiredness, lower number of certain types of white blood cells (neutropenia,
lymphopenia, leukopenia), muscle pain, flu-like illness, rash, increased blood
cholesterol levels, increased liver enzyme levels, pneumonia, low number of red
blood cells (anemia), and infection of the stomach and intestine
(gastroenteritis).
A separation or tear to the lining of the back part of the eye (retinal
detachment) has happened in people with atopic dermatitis treated with RINVOQ.
Call your HCP right away if you have any sudden changes in your vision during
treatment with RINVOQ.
Some people taking RINVOQ may see medicine residue (a whole tablet or tablet
pieces) in their stool. If this happens, call your healthcare provider.
These are not all the possible side effects of RINVOQ.
How should I take RINVOQ?
RINVOQ is taken once a day with or without food. Do not split, crush, or chew
the tablet. Take RINVOQ exactly as your HCP tells you to use it. RINVOQ is
available in 15 mg, 30 mg, and 45 mg extended-release tablets.
This is the most important information to know about RINVOQ. For more
information, talk to your HCP.
You are encouraged to report negative side effects of prescription drugs to the
FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
USES
RINVOQ is a prescription medicine used to treat:
* Adults with moderate to severe rheumatoid arthritis (RA) when 1 or more
medicines called tumor necrosis factor (TNF) blockers have been used, and did
not work well or could not be tolerated.
* Adults with active psoriatic arthritis (PsA) when 1 or more medicines called
TNF blockers have been used, and did not work well or could not be tolerated.
* Adults with active ankylosing spondylitis (AS) when 1 or more medicines
called TNF blockers have been used, and did not work well or could not be
tolerated.
* Adults with active non-radiographic axial spondyloarthritis (nr-axSpA) with
objective signs of inflammation when a TNF blocker medicine has been used,
and did not work well or could not be tolerated.
* Adults with moderate to severe ulcerative colitis (UC) when 1 or more
medicines called TNF blockers have been used, and did not work well or could
not be tolerated.
* Adults with moderate to severe Crohn's disease (CD) when 1 or more medicines
called TNF blockers have been used, and did not work well or could not be
tolerated.
It is not known if RINVOQ is safe and effective in children with juvenile
idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis,
non-radiographic axial spondyloarthritis, ulcerative colitis, or Crohn's
disease.
* Adults and children 12 years of age and older with moderate to severe eczema
(atopic dermatitis [AD]) that did not respond to previous treatment and their
eczema is not well controlled with other pills or injections, including
biologic medicines, or the use of other pills or injections is not
recommended.
RINVOQ is safe and effective in children 12 years of age and older weighing at
least 88 pounds (40 kg) with atopic dermatitis.
It is not known if RINVOQ is safe and effective in children under 12 years of
age with atopic dermatitis.
If you are having difficulty paying for your medicine, AbbVie may be able to
help. Visit AbbVie.com/myAbbVieAssist to learn more.
US-RNQ-220259
Please see the Full Prescribing Information, including the Medication Guide, for
RINVOQ.
Legal Notices/Privacy Policy. © 2023 AbbVie. All rights reserved. If you have
any questions about AbbVie's RINVOQ.com website that have not been
answered, click here. This website and the information contained herein is
intended for use by US residents only, is provided for informational purposes
only and is not intended to replace a discussion with a healthcare provider. All
decisions regarding patient care must be made with a healthcare provider and
consider the unique characteristics of each patient.
RINVOQ (UPADACITINIB)
* Active Psoriatic Arthritis Home
* RINVOQ Results
* Appointment Checklist
* RINVOQ Complete
* Cost & Savings
* Sitemap
IMPORTANT INFORMATION FOR PATIENTS
* Important Safety Information
* Medication Guide
* Full Prescribing Information (English)
INFORMATION FROM ABBVIE
* Healthcare Professionals Site
* COVID-19 Information
* Accessibility Statement
* Contact Us
* Terms of Use
* Privacy Notice
* Cookies Settings
* Your Privacy Choices
US-RNQR-230391
TERMS AND CONDITIONS
AbbVie Inc. is providing this service to help patients find rheumatologists in
their area who have experience with RINVOQ (upadacitinib).
No fees have been received by or paid to rheumatologists for inclusion in this
specialist locator directory. Inclusion of a physician in this directory does
not represent an endorsement by or a recommendation from AbbVie Inc., nor does
it imply that the rheumatologists on the list will determine that RINVOQ is
right for you.
You are ultimately responsible for the selection of a physician and it is an
important decision that you should consider carefully. This rheumatologist
locator tool is just one source of information available to you. AbbVie Inc. is
the maker and marketer of RINVOQ (upadacitinib).
Close
US-RNQR-210387
LEAVING ABBVIE WEB SITE
You are leaving the RINVOQ (upadacitinib) site and connecting to a site that is
not under the control of AbbVie. AbbVie is not responsible for the contents of
any such site or any further links from such site. AbbVie is providing these
links to you only as a convenience and the inclusion of any link does not imply
the endorsement of the linked site by AbbVie. You should also be aware that the
linked site may be governed by its own set of terms and conditions and privacy
policy for which AbbVie has no responsibility. Conversely, the presence of this
link does not imply the linked site's endorsement of RINVOQ.com or AbbVie.
Do you wish to leave this site?
Yes
No
US-RNQR-210387
YOU ARE NOW LEAVING THE RINVOQ WEBSITE
By clicking “Agree and continue” below, you acknowledge and agree that AbbVie
does not, in any way, endorse or recommend Doctor.com, the qualifications of any
physician associated with Doctor.com, or the quality of medical care any of
those physicians can provide. Please be aware that Doctor.com may have its own
set of terms and conditions and privacy policy for which AbbVie has no
responsibility. If you agree to the above, click “Agree and continue” to proceed
to Doctor.com. If you do not agree to the above, click “Cancel” to remain on
RINVOQ.com.
Agree and continue
Cancel
US-RNQR-210512
LEAVING ABBVIE WEB SITE
You are leaving the RINVOQ (upadacitinib) site and connecting to a site that is
not under the control of AbbVie. AbbVie is not responsible for the contents of
any such site or any further links from such site. AbbVie is providing these
links to you only as a convenience and the inclusion of any link does not imply
the endorsement of the linked site by AbbVie. You should also be aware that the
linked site may be governed by its own set of terms and conditions and privacy
policy for which AbbVie has no responsibility. Conversely, the presence of this
link does not imply the linked site's endorsement of RINVOQ.com or AbbVie.
Do you wish to leave this site?
Yes
No
US-RNQR-220513
US HEALTHCARE
PROFESSIONALS ONLY
You are about to enter a site that is for US healthcare professionals only. By
continuing, you certify that you are a healthcare professional and that you wish
to proceed to the healthcare professionals section of this site. Products or
treatments described on this site are available in the US but may not be
available in all other countries.
I am a licensed healthcare professional and wish to proceed to the healthcare
professionals section of this site.
Yes
No
US-RNQ-220010
LEAVING ABBVIE WEB SITE
You are leaving the RINVOQ (upadacitinib) site and connecting to a site that is
not under the control of AbbVie. AbbVie is not responsible for the contents of
any such site or any further links from such site. AbbVie is providing these
links to you only as a convenience and the inclusion of any link does not imply
the endorsement of the linked site by AbbVie. You should also be aware that the
linked site may be governed by its own set of terms and conditions and privacy
policy for which AbbVie has no responsibility. Conversely, the presence of this
link does not imply the linked site's endorsement of RINVOQ.com or AbbVie.
Do you wish to leave this site?
Yes
No
US-RNQ-220499
US HEALTHCARE
PROFESSIONALS ONLY
You are about to enter a site that is for US healthcare professionals only. By
continuing, you certify that you are a healthcare professional and that you wish
to proceed to the healthcare professionals section of this site. Products or
treatments described on this site are available in the US but may not be
available in all other countries.
I am a licensed healthcare professional and wish to proceed to the healthcare
professionals section of this site.
Yes
No
US-RNQ-220499
TERMS AND CONDITIONS
AbbVie Inc. is providing this service to help patients find rheumatologists in
their area who have experience with RINVOQ (upadacitinib).
No fees have been received by or paid to rheumatologists for inclusion in this
specialist locator directory. Inclusion of a physician in this directory does
not represent an endorsement by or a recommendation from AbbVie Inc., nor does
it imply that the rheumatologists on the list will determine that RINVOQ is
right for you.
You are ultimately responsible for the selection of a physician and it is an
important decision that you should consider carefully. This rheumatologist
locator tool is just one source of information available to you. AbbVie Inc. is
the maker and marketer of RINVOQ (upadacitinib).
Close
US-RNQR-210387
IMPORTANT SAFETY INFORMATION
What is the most important information I should know about RINVOQ?
RINVOQ may cause serious side effects, including:
* Serious infections. RINVOQ can lower your ability to fight infections.
Serious infections have happened while taking RINVOQ, including tuberculosis
(TB) and infections caused by bacteria, fungi, or viruses that can spread
throughout the body. Some people have died from these infections. Your
healthcare provider (HCP) should test you for TB before starting RINVOQ and
check you closely for signs and symptoms of TB during treatment with RINVOQ.
You should not start taking RINVOQ if you have any kind of infection unless
your HCP tells you it is okay. If you get a serious infection, your HCP may
stop your treatment until your infection is controlled. You may be at higher
risk of developing shingles (herpes zoster).
* Increased risk of death in people 50 years and older who have at least 1
heart disease (cardiovascular) risk factor.
* Cancer and immune system problems. RINVOQ may increase your risk of certain
cancers. Lymphoma and other cancers, including skin cancers, can happen.
Current or past smokers are at higher risk of certain cancers, including
lymphoma and lung cancer. Follow your HCP's advice about having your skin
checked for skin cancer during treatment with RINVOQ. Limit the amount of
time you spend in sunlight. Wear protective clothing when you are in the sun
and use sunscreen.
* Increased risk of major cardiovascular (CV) events, such as heart attack,
stroke, or death, in people 50 years and older who have at least 1 heart
disease (CV) risk factor, especially if you are a current or past smoker.
* Blood clots. Blood clots in the veins of the legs or lungs and arteries can
happen with RINVOQ. This may be life-threatening and cause death. Blood clots
in the veins of the legs and lungs have happened more often in people who are
50 years and older and with at least 1 heart disease (CV) risk factor.
* Allergic reactions. Symptoms such as rash (hives), trouble breathing, feeling
faint or dizzy, or swelling of your lips, tongue, or throat, that may mean
you are having an allergic reaction have been seen in people taking RINVOQ.
Some of these reactions were serious. If any of these symptoms occur during
treatment with RINVOQ, stop taking RINVOQ and get emergency medical help
right away.
* Tears in the stomach or intestines. This happens most often in people who
take nonsteroidal anti-inflammatory drugs (NSAIDs) or corticosteroids. Get
medical help right away if you get stomach-area pain, fever, chills, nausea,
or vomiting.
* Changes in certain laboratory tests. Your HCP should do blood tests before
you start taking RINVOQ and while you take it. Your HCP may stop your RINVOQ
treatment for a period of time if needed because of changes in these blood
test results.
Do not take RINVOQ if you are allergic to upadacitinib or any of the ingredients
in RINVOQ. See the Medication Guide or Consumer Brief Summary for a complete
list of ingredients.
What should I tell my HCP BEFORE starting RINVOQ?
Tell your HCP if you:
* Are being treated for an infection, have an infection that won't go away or
keeps coming back, or have symptoms of an infection, such as:
* - Fever, sweating, or chills
* - Shortness of breath
* - Warm, red, or painful skin or sores on your body
* - Muscle aches
* - Feeling tired
* - Blood in phlegm
* - Diarrhea or stomach pain
* - Cough
* - Weight loss
* - Burning when urinating or urinating more often than normal
* Have TB or have been in close contact with someone with TB.
* Are a current or past smoker.
* Have had a heart attack, other heart problems, or stroke.
* Have or have had any type of cancer, hepatitis B or C, shingles (herpes
zoster), blood clots in the veins of your legs or lungs, diverticulitis
(inflammation in parts of the large intestine), or ulcers in your stomach or
intestines.
* Have other medical conditions, including liver problems, low blood cell
counts, diabetes, chronic lung disease, HIV, or a weak immune system.
* Live, have lived, or have traveled to parts of the country, such as the Ohio
and Mississippi River valleys and the Southwest, that increase your risk of
getting certain kinds of fungal infections. If you are unsure if you've been
to these types of areas, ask your HCP.
* Have recently received or are scheduled to receive a vaccine. People who take
RINVOQ should not receive live vaccines.
* Are pregnant or plan to become pregnant. Based on animal studies, RINVOQ may
harm your unborn baby. Your HCP will check whether or not you are pregnant
before you start RINVOQ. You should use effective birth control
(contraception) to avoid becoming pregnant during treatment with RINVOQ and
for 4 weeks after your last dose.
* There is a pregnancy surveillance program for RINVOQ. The purpose of the
program is to collect information about the health of you and your baby. If
you become pregnant while taking RINVOQ, you are encouraged to report the
pregnancy by calling 1-800-633-9110.
* Are breastfeeding or plan to breastfeed. RINVOQ may pass into your breast
milk. Do not breastfeed during treatment with RINVOQ and for 6 days after
your last dose.
Tell your HCP about all the medicines you take, including prescription and
over-the-counter medicines, vitamins, and herbal supplements. RINVOQ and other
medicines may affect each other, causing side effects.
Especially tell your HCP if you take:
* Medicines for fungal or bacterial infections
* Rifampicin or phenytoin
* Medicines that affect your immune system
If you are not sure if you are taking any of these medicines, ask your HCP or
pharmacist.
What should I avoid while taking RINVOQ?
Avoid food or drink containing grapefruit during treatment with RINVOQ as it may
increase the risk of side effects.
What should I do or tell my HCP AFTER starting RINVOQ?
* Tell your HCP right away if you have any symptoms of an infection. RINVOQ can
make you more likely to get infections or make any infections you have worse.
* Get emergency help right away if you have any symptoms of a heart attack or
stroke while taking RINVOQ, including:
* - Discomfort in the center of your chest that lasts for more than a few
minutes or that goes away and comes back
* - Severe tightness, pain, pressure, or heaviness in your chest, throat,
neck, or jaw
* - Pain or discomfort in your arms, back, neck, jaw, or stomach
* - Shortness of breath with or without chest discomfort
* - Breaking out in a cold sweat
* - Nausea or vomiting
* - Feeling lightheaded
* - Weakness in one part or on one side of your body
* - Slurred speech
* Tell your HCP right away if you have any signs or symptoms of blood clots
during treatment with RINVOQ, including:
* - Swelling
* - Pain or tenderness in one or both legs
* - Sudden unexplained chest or upper back pain
* - Shortness of breath or difficulty breathing
*
*
* Tell your HCP right away if you have a fever or stomach-area pain that does
not go away, and a change in your bowel habits.
What are other possible side effects of RINVOQ?
Common side effects include upper respiratory tract infections (common cold,
sinus infections), shingles (herpes zoster), herpes simplex virus infections
(including cold sores), bronchitis, nausea, cough, fever, acne, headache,
increased blood levels of creatine phosphokinase, allergic reactions,
inflammation of hair follicles, stomach-area (abdominal) pain, increased weight,
flu, tiredness, lower number of certain types of white blood cells (neutropenia,
lymphopenia, leukopenia), muscle pain, flu-like illness, rash, increased blood
cholesterol levels, increased liver enzyme levels, pneumonia, low number of red
blood cells (anemia), and infection of the stomach and intestine
(gastroenteritis).
A separation or tear to the lining of the back part of the eye (retinal
detachment) has happened in people with atopic dermatitis treated with RINVOQ.
Call your HCP right away if you have any sudden changes in your vision during
treatment with RINVOQ.
Some people taking RINVOQ may see medicine residue (a whole tablet or tablet
pieces) in their stool. If this happens, call your healthcare provider.
These are not all the possible side effects of RINVOQ.
How should I take RINVOQ?
RINVOQ is taken once a day with or without food. Do not split, crush, or chew
the tablet. Take RINVOQ exactly as your HCP tells you to use it. RINVOQ is
available in 15 mg, 30 mg, and 45 mg extended-release tablets.
This is the most important information to know about RINVOQ. For more
information, talk to your HCP.
You are encouraged to report negative side effects of prescription drugs to the
FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
USES
RINVOQ is a prescription medicine used to treat:
* Adults with moderate to severe rheumatoid arthritis (RA) when 1 or more
medicines called tumor necrosis factor (TNF) blockers have been used, and did
not work well or could not be tolerated.
* Adults with active psoriatic arthritis (PsA) when 1 or more medicines called
TNF blockers have been used, and did not work well or could not be tolerated.
* Adults with active ankylosing spondylitis (AS) when 1 or more medicines
called TNF blockers have been used, and did not work well or could not be
tolerated.
* Adults with active non-radiographic axial spondyloarthritis (nr-axSpA) with
objective signs of inflammation when a TNF blocker medicine has been used,
and did not work well or could not be tolerated.
* Adults with moderate to severe ulcerative colitis (UC) when 1 or more
medicines called TNF blockers have been used, and did not work well or could
not be tolerated.
* Adults with moderate to severe Crohn's disease (CD) when 1 or more medicines
called TNF blockers have been used, and did not work well or could not be
tolerated.
It is not known if RINVOQ is safe and effective in children with juvenile
idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis,
non-radiographic axial spondyloarthritis, ulcerative colitis, or Crohn's
disease.
* Adults and children 12 years of age and older with moderate to severe eczema
(atopic dermatitis [AD]) that did not respond to previous treatment and their
eczema is not well controlled with other pills or injections, including
biologic medicines, or the use of other pills or injections is not
recommended.
RINVOQ is safe and effective in children 12 years of age and older weighing at
least 88 pounds (40 kg) with atopic dermatitis.
It is not known if RINVOQ is safe and effective in children under 12 years of
age with atopic dermatitis.
If you are having difficulty paying for your medicine, AbbVie may be able to
help. Visit AbbVie.com/myAbbVieAssist to learn more.
US-RNQ-220259
Please see the Full Prescribing Information, including the Medication Guide, for
RINVOQ.
Legal Notices/Privacy Policy. © 2023 AbbVie. All rights reserved. If you have
any questions about AbbVie's RINVOQ.com website that have not been
answered, click here. This website and the information contained herein is
intended for use by US residents only, is provided for informational purposes
only and is not intended to replace a discussion with a healthcare provider. All
decisions regarding patient care must be made with a healthcare provider and
consider the unique characteristics of each patient.
LEAVING ABBVIE WEB SITE
You are leaving the RINVOQ (upadacitinib) site and connecting to a site that is
not under the control of AbbVie. AbbVie is not responsible for the contents of
any such site or any further links from such site. AbbVie is providing these
links to you only as a convenience and the inclusion of any link does not imply
the endorsement of the linked site by AbbVie. You should also be aware that the
linked site may be governed by its own set of terms and conditions and privacy
policy for which AbbVie has no responsibility. Conversely, the presence of this
link does not imply the linked site's endorsement of RINVOQ.com or AbbVie.
Do you wish to leave this site?
Yes
No
US-RNQG-230183
LEAVING ABBVIE WEB SITE
You are leaving the RINVOQ (upadacitinib) site and connecting to a site that is
not under the control of AbbVie. AbbVie is not responsible for the contents of
any such site or any further links from such site. AbbVie is providing these
links to you only as a convenience and the inclusion of any link does not imply
the endorsement of the linked site by AbbVie. You should also be aware that the
linked site may be governed by its own set of terms and conditions and privacy
policy for which AbbVie has no responsibility. Conversely, the presence of this
link does not imply the linked site's endorsement of RINVOQ.com or AbbVie.
Do you wish to leave this site?
US-RNQR-190268
LEAVING ABBVIE WEB SITE
You are leaving the RINVOQ (upadacitinib) site and connecting to a site that is
not under the control of AbbVie. AbbVie is not responsible for the contents of
any such site or any further links from such site. AbbVie is providing these
links to you only as a convenience and the inclusion of any link does not imply
the endorsement of the linked site by AbbVie. You should also be aware that the
linked site may be governed by its own set of terms and conditions and privacy
policy for which AbbVie has no responsibility. Conversely, the presence of this
link does not imply the linked site's endorsement of RINVOQ.com or AbbVie.
Do you wish to leave this site?
Yes
No
US-RNQR-220513
YOU ARE NOW LEAVING THE RINVOQ WEBSITE
By clicking “Agree and continue” below, you acknowledge and agree that AbbVie
does not, in any way, endorse or recommend Doctor.com, the qualifications of any
physician associated with Doctor.com, or the quality of medical care any of
those physicians can provide. Please be aware that Doctor.com may have its own
set of terms and conditions and privacy policy for which AbbVie has no
responsibility. If you agree to the above, click “Agree and continue” to proceed
to Doctor.com. If you do not agree to the above, click “Cancel” to remain on
RINVOQ.com.
Agree and continue
Cancel
US-RNQR-220513
LEAVING ABBVIE WEB SITE
You are leaving the RINVOQ (upadacitinib) site and connecting to a site that is
not under the control of AbbVie. AbbVie is not responsible for the contents of
any such site or any further links from such site. AbbVie is providing these
links to you only as a convenience and the inclusion of any link does not imply
the endorsement of the linked site by AbbVie. You should also be aware that the
linked site may be governed by its own set of terms and conditions and privacy
policy for which AbbVie has no responsibility. Conversely, the presence of this
link does not imply the linked site's endorsement of RINVOQ.com or AbbVie.
Do you wish to leave this site?
Yes
No
US-RNQR-221299
US HEALTHCARE
PROFESSIONALS ONLY
You are about to enter a site that is for US healthcare professionals only. By
continuing, you certify that you are a healthcare professional and that you wish
to proceed to the healthcare professionals section of this site. Products or
treatments described on this site are available in the US but may not be
available in all other countries.
I am a licensed healthcare professional and wish to proceed to the healthcare
professionals section of this site.
Yes
No
US-RNQ-220010
US HEALTHCARE
PROFESSIONALS ONLY
You are about to enter a site that is for US healthcare professionals only. By
continuing, you certify that you are a healthcare professional and that you wish
to proceed to the healthcare professionals section of this site. Products or
treatments described on this site are available in the US but may not be
available in all other countries.
I am a licensed healthcare professional and wish to proceed to the healthcare
professionals section of this site.
Yes
No
US-RNQ-220010
IMPORTANT SAFETY INFORMATION & USE
Warning: Serious Infections, Increased Risk of Death, Cancer, Major
Cardiovascular Events, Blood Clots
IMPORTANT SAFETY INFORMATION & USE
Warning: Serious Infections, Increased Risk of Death, Cancer, Major
Cardiovascular Events, Blood Clots
IMPORTANT SAFETY INFORMATION & USE
Warning: Serious Infections, Increased Risk of Death, Cancer, Major
Cardiovascular Events, Blood Clots
IMPORTANT SAFETY INFORMATION & USE
Warning: Serious Infections, Increased Risk of Death, Cancer, Major
Cardiovascular Events, Blood Clots
USE
RINVOQ is a prescription medicine used to treat adults with active psoriatic
arthritis when 1 or more medicines called tumor necrosis factor (TNF) blockers
have been used, and did not work well or could not be tolerated. It is not known
if RINVOQ is safe and effective in children with psoriatic arthritis.
IMPORTANT SAFETY INFORMATION
What is the most important information I should know about RINVOQ?
RINVOQ may cause serious side effects, including:
* Serious infections. RINVOQ can lower your ability to fight infections.
Serious infections have happened while taking RINVOQ, including tuberculosis
(TB) and infections caused by bacteria, fungi, or viruses that can spread
throughout the body. Some people have died from these infections. Your
healthcare provider (HCP) should test you for TB before starting RINVOQ and
check you closely for signs and symptoms of TB during treatment with RINVOQ.
You should not start taking RINVOQ if you have any kind of infection unless
your HCP tells you it is okay. If you get a serious infection, your HCP may
stop your treatment until your infection is controlled. You may be at higher
risk of developing shingles (herpes zoster).
* Increased risk of death in people 50 years and older who have at least 1
heart disease (cardiovascular) risk factor.
* Cancer and immune system problems. RINVOQ may increase your risk of certain
cancers. Lymphoma and other cancers, including skin cancers, can happen.
Current or past smokers are at higher risk of certain cancers, including
lymphoma and lung cancer. Follow your HCP's advice about having your skin
checked for skin cancer during treatment with RINVOQ. Limit the amount of
time you spend in sunlight. Wear protective clothing when you are in the sun
and use sunscreen.
* Increased risk of major cardiovascular (CV) events, such as heart attack,
stroke, or death, in people 50 years and older who have at least 1 heart
disease (CV) risk factor, especially if you are a current or past smoker.
* Blood clots. Blood clots in the veins of the legs or lungs and arteries can
happen with RINVOQ. This may be life-threatening and cause death. Blood clots
in the veins of the legs and lungs have happened more often in people who are
50 years and older and with at least 1 heart disease (CV) risk factor.
* Allergic reactions. Symptoms such as rash (hives), trouble breathing, feeling
faint or dizzy, or swelling of your lips, tongue, or throat, that may mean
you are having an allergic reaction have been seen in people taking RINVOQ.
Some of these reactions were serious. If any of these symptoms occur during
treatment with RINVOQ, stop taking RINVOQ and get emergency medical help
right away.
* Tears in the stomach or intestines. This happens most often in people who
take nonsteroidal anti-inflammatory drugs (NSAIDs) or corticosteroids. Get
medical help right away if you get stomach-area pain, fever, chills, nausea,
or vomiting.
* Changes in certain laboratory tests. Your HCP should do blood tests before
you start taking RINVOQ and while you take it. Your HCP may stop your RINVOQ
treatment for a period of time if needed because of changes in these blood
test results.
Do not take RINVOQ if you are allergic to upadacitinib or any of the ingredients
in RINVOQ. See the Medication Guide or Consumer Brief Summary for a complete
list of ingredients.
What should I tell my HCP BEFORE starting RINVOQ?
Tell your HCP if you:
* Are being treated for an infection, have an infection that won't go away or
keeps coming back, or have symptoms of an infection, such as:
* - Fever, sweating, or chills
* - Shortness of breath
* - Warm, red, or painful skin or sores on your body
* - Muscle aches
* - Feeling tired
* - Blood in phlegm
* - Diarrhea or stomach pain
* - Cough
* - Weight loss
* - Burning when urinating or urinating more often than normal
* Have TB or have been in close contact with someone with TB.
* Are a current or past smoker.
* Have had a heart attack, other heart problems, or stroke.
* Have or have had any type of cancer, hepatitis B or C, shingles (herpes
zoster), blood clots in the veins of your legs or lungs, diverticulitis
(inflammation in parts of the large intestine), or ulcers in your stomach or
intestines.
* Have other medical conditions, including liver problems, low blood cell
counts, diabetes, chronic lung disease, HIV, or a weak immune system.
* Live, have lived, or have traveled to parts of the country, such as the Ohio
and Mississippi River valleys and the Southwest, that increase your risk of
getting certain kinds of fungal infections. If you are unsure if you've been
to these types of areas, ask your HCP.
* Have recently received or are scheduled to receive a vaccine. People who take
RINVOQ should not receive live vaccines.
* Are pregnant or plan to become pregnant. Based on animal studies, RINVOQ may
harm your unborn baby. Your HCP will check whether or not you are pregnant
before you start RINVOQ. You should use effective birth control
(contraception) to avoid becoming pregnant during treatment with RINVOQ and
for 4 weeks after your last dose.
* There is a pregnancy surveillance program for RINVOQ. The purpose of the
program is to collect information about the health of you and your baby. If
you become pregnant while taking RINVOQ, you are encouraged to report the
pregnancy by calling 1-800-633-9110.
* Are breastfeeding or plan to breastfeed. RINVOQ may pass into your breast
milk. Do not breastfeed during treatment with RINVOQ and for 6 days after
your last dose.
Tell your HCP about all the medicines you take, including prescription and
over-the-counter medicines, vitamins, and herbal supplements. RINVOQ and other
medicines may affect each other, causing side effects.
Especially tell your HCP if you take:
* Medicines for fungal or bacterial infections
* Rifampicin or phenytoin
* Medicines that affect your immune system
If you are not sure if you are taking any of these medicines, ask your HCP or
pharmacist.
What should I avoid while taking RINVOQ?
Avoid food or drink containing grapefruit during treatment with RINVOQ as it may
increase the risk of side effects.
What should I do or tell my HCP AFTER starting RINVOQ?
* Tell your HCP right away if you have any symptoms of an infection. RINVOQ can
make you more likely to get infections or make any infections you have worse.
* Get emergency help right away if you have any symptoms of a heart attack or
stroke while taking RINVOQ, including:
* - Discomfort in the center of your chest that lasts for more than a few
minutes or that goes away and comes back
* - Severe tightness, pain, pressure, or heaviness in your chest, throat,
neck, or jaw
* - Pain or discomfort in your arms, back, neck, jaw, or stomach
* - Shortness of breath with or without chest discomfort
* - Breaking out in a cold sweat
* - Nausea or vomiting
* - Feeling lightheaded
* - Weakness in one part or on one side of your body
* - Slurred speech
* Tell your HCP right away if you have any signs or symptoms of blood clots
during treatment with RINVOQ, including:
* - Swelling
* - Pain or tenderness in one or both legs
* - Sudden unexplained chest or upper back pain
* - Shortness of breath or difficulty breathing
*
*
* Tell your HCP right away if you have a fever or stomach-area pain that does
not go away, and a change in your bowel habits.
What are other possible side effects of RINVOQ?
Common side effects include upper respiratory tract infections (common cold,
sinus infections), shingles (herpes zoster), herpes simplex virus infections
(including cold sores), bronchitis, nausea, cough, fever, acne, headache,
increased blood levels of creatine phosphokinase, allergic reactions,
inflammation of hair follicles, stomach-area (abdominal) pain, increased weight,
flu, tiredness, lower number of certain types of white blood cells (neutropenia,
lymphopenia, leukopenia), muscle pain, flu-like illness, rash, increased blood
cholesterol levels, increased liver enzyme levels, pneumonia, low number of red
blood cells (anemia), and infection of the stomach and intestine
(gastroenteritis).
A separation or tear to the lining of the back part of the eye (retinal
detachment) has happened in people with atopic dermatitis treated with RINVOQ.
Call your HCP right away if you have any sudden changes in your vision during
treatment with RINVOQ.
Some people taking RINVOQ may see medicine residue (a whole tablet or tablet
pieces) in their stool. If this happens, call your healthcare provider.
These are not all the possible side effects of RINVOQ.
How should I take RINVOQ?
RINVOQ is taken once a day with or without food. Do not split, crush, or chew
the tablet. Take RINVOQ exactly as your HCP tells you to use it. RINVOQ is
available in 15 mg, 30 mg, and 45 mg extended-release tablets.
This is the most important information to know about RINVOQ. For more
information, talk to your HCP.
You are encouraged to report negative side effects of prescription drugs to the
FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
USES
RINVOQ is a prescription medicine used to treat:
* Adults with moderate to severe rheumatoid arthritis (RA) when 1 or more
medicines called tumor necrosis factor (TNF) blockers have been used, and did
not work well or could not be tolerated.
* Adults with active psoriatic arthritis (PsA) when 1 or more medicines called
TNF blockers have been used, and did not work well or could not be tolerated.
* Adults with active ankylosing spondylitis (AS) when 1 or more medicines
called TNF blockers have been used, and did not work well or could not be
tolerated.
* Adults with active non-radiographic axial spondyloarthritis (nr-axSpA) with
objective signs of inflammation when a TNF blocker medicine has been used,
and did not work well or could not be tolerated.
* Adults with moderate to severe ulcerative colitis (UC) when 1 or more
medicines called TNF blockers have been used, and did not work well or could
not be tolerated.
* Adults with moderate to severe Crohn's disease (CD) when 1 or more medicines
called TNF blockers have been used, and did not work well or could not be
tolerated.
It is not known if RINVOQ is safe and effective in children with juvenile
idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis,
non-radiographic axial spondyloarthritis, ulcerative colitis, or Crohn's
disease.
* Adults and children 12 years of age and older with moderate to severe eczema
(atopic dermatitis [AD]) that did not respond to previous treatment and their
eczema is not well controlled with other pills or injections, including
biologic medicines, or the use of other pills or injections is not
recommended.
RINVOQ is safe and effective in children 12 years of age and older weighing at
least 88 pounds (40 kg) with atopic dermatitis.
It is not known if RINVOQ is safe and effective in children under 12 years of
age with atopic dermatitis.
If you are having difficulty paying for your medicine, AbbVie may be able to
help. Visit AbbVie.com/myAbbVieAssist to learn more.
US-RNQ-220259
Please see the Full Prescribing Information, including the Medication Guide, for
RINVOQ.
Legal Notices/Privacy Policy. © 2023 AbbVie. All rights reserved. If you have
any questions about AbbVie's RINVOQ.com website that have not been
answered, click here. This website and the information contained herein is
intended for use by US residents only, is provided for informational purposes
only and is not intended to replace a discussion with a healthcare provider. All
decisions regarding patient care must be made with a healthcare provider and
consider the unique characteristics of each patient.
AbbVie may use and disclose online usage data about you collected automatically
through online tracking technologies such as cookies, pixels, and web beacons
(collectively, “cookies”). We use this data for multiple purposes, including for
online targeted advertising (advertisements based on your interests inferred
from your activity across other unaffiliated sites and services) and website
analytics purposes, as well as to personalize content, save your preferences,
provide social media features, and track the site’s performance, as further
described in the"Cookies and similar tracking and data collection technologies"
section of our Privacy Notice. We retain this data for as long as necessary to
fulfill these purposes or as needed to comply with our record retention
obligations. We do not sell your data, but we may disclose it to our marketing
and advertising partners for purposes of online targeted advertising or for
website analytics purposes. To opt out of the use or disclosure of your
cookie-based personal data for online targeted advertising or for website
analytics purposes, or to otherwise manage your preferences, please click on
Cookie Settings below. For additional information on the categories of data we
collect, the purposes for their collection, disclosures to third parties, and
data retention, please visit ourPrivacy Notice.
Cookies Settings
PRIVACY PREFERENCE CENTER
You can choose not to allow some types of cookies. Click on the different
category headings to find out more and change our default settings. However,
blocking some types of cookies may impact your experience of the site and the
services we are able to offer.
Depending on the jurisdiction where you live, you may have the right to opt out
of the use and disclosure of your personal data for purposes of online targeted
advertising (advertisements based on your interests inferred from your activity
across other unaffiliated sites and services) or website analytics (to
understand website usage behavior and receive website analytics). To opt out of
the use and disclosure of your cookie-based personal data for these purposes,
you can toggle off “Functional” (for website analytics) and/or “Advertising”
(for online targeted advertising) below.
To opt out of the use and disclosure of your non-cookie-based information for
online targeted advertising purposes, please also click"Your Privacy Choices" on
our website.
Note that if we recognize your Global Privacy Control (GPC) as enabled, our
policy is to opt you out of the use or disclosure of your cookie-based personal
data for online targeted advertising and website analytics purposes for the
browser or device on which you have GPC enabled. However, unless you are logged
in to an AbbVie account that has the capability to link the personal data we
have about you to your browser or device, we cannot apply your GPC opt-out
request to your non-cookie based personal data because the connection between
your browser or device is not known to us. Thus, if you have GPC enabled, please
click"Your Privacy Choices" to opt out of the disclosure of your non-cookie
based personal data for these purposes.
MANAGE CONSENT PREFERENCES
REQUIRED COOKIES
Always Active
These cookies are necessary for the website to function and cannot be switched
off in our systems. They may be set by us or by third party providers whose
services we have added to our pages. They are usually only set in response to
actions made by you which amount to a request for services, such as setting your
privacy preferences, logging in or filling in forms. You can set your browser to
block or alert you about these cookies, but some parts of the site will not then
work.
View Vendor Details
FUNCTIONAL COOKIES
Functional Cookies
These cookies allow us to count visits and traffic sources so we can measure and
improve the performance of our site. They may be set by us or by third party
providers whose services we have added to our pages. They help us to know which
pages are the most and least popular and see how visitors move around the site.
View Vendor Details
ADVERTISING COOKIES
Advertising Cookies
These cookies may be set through our site by our advertising partners to build a
profile of your interests and show you relevant adverts on other sites. They do
not store directly personal information but are based on uniquely identifying
your browser and internet device. If you do not allow these cookies, you will
experience less targeted advertising, but you will still receive online
advertising.
View Vendor Details
Back Button
PERFORMANCE COOKIES
Search Icon
Filter Icon
Clear
checkbox label label
Apply Cancel
Consent Leg.Interest
checkbox label label
checkbox label label
checkbox label label
*
View Cookies
* Name
cookie name
Confirm My Choices